Pernix Therapeutics Added to Russell Microcap® Index

MORRISTOWN, N.J., June 28, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. PTX ("Pernix" or the "Company"), announced today that it has been added to the Russell Microcap^® index following the annual reconstitution, which took effect after the US market closed on Friday, June 23^rd.

"We are pleased to be included in the Russell Microcap Index," said John Sedor, Chairman and Chief Executive Officer of Pernix Therapeutics.  "The Russell US Indexes are some of the leading US equity benchmarks for institutional investors.  We believe inclusion in the Russell Microcap Index should increase our visibility in the financial marketplace and broaden our shareholder base since Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies."

About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market.  The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments.  The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.

To learn more about Pernix Therapeutics, visit www.pernixtx.com.

Treximet® and Silenor® are registered trademarks of Pernix Therapeutics Holdings, Inc.
Zohydro® ER is a registered trademark of Pernix Therapeutics Holdings, Inc.
BeadTek™ is a trademark used by Pernix under license.

CONTACT
Investor Relations
Matthew P. Duffy, 212-915-0685
LifeSci Advisors, LLC
matthew@lifesciadvisors.com